News & Updates

Blood cadmium may signal osteoporosis-related fractures among never-smokers

Increased concentrations of cadmium in the blood are associated with a heightened risk of developing osteoporosis-related fractures among individuals who have never smoked, according to a study.

Teplizumab preserves ß-cell function in children with new-onset T1D

Treatment with teplizumab significantly preserved beta(ß)-cell function, as measured by C-peptide levels, in children and adolescents with new-onset type 1 diabetes (T1D) compared with placebo, according to the PROTECT* study.

Mood, fatigue poorly addressed in post-stroke return-to-work rehab programmes

Despite being significant predictors of return to work (RTW), mood and fatigue are poorly addressed in rehabilitation programmes aimed at improving RTW following a stroke, a systematic review from Singapore suggests.

Gliclazide Diabetes Mellitus D

Original New Drug Application Approvals by US FDA (16-30 November 2023)

New drug applications approved by US FDA as of 16-30 November  2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Depression poses no significant risk of subclinical coronary atherosclerosis

Individuals with depression do not appear to be at increased risk of subclinical coronary atherosclerosis, according to a study.

Very early HIV treatment may help babies live medication-free

Initiating antiretroviral therapy (ART) within 48 hours of life for infants born with HIV can lead to sustained viral suppression, as reflected by reduced HIV reservoirs by age 2 years, which suggests the possibility of an ART-free remission.

NAFLD progression may raise ESLD risk

Histological disease progression in patients with nonalcoholic fatty liver disease (NAFLD) is significantly associated with a higher rate of developing incident end-stage liver disease (ESLD) but not with all-cause mortality, a study has shown.